NeuroCFD: A game changer for patients with neurovascular disease

Personalized medicine promises to resolve some of the key challenges in today’s healthcare ecosystem. The global market size of personalized medicine surpassed $59.16 billion in 2019 and expected to reach $141.33 billion by 2027. Medical simulation is one of the key drivers of personalized medicine. Medical simulation market is projected to reach USD 3.7 billion by 2025 from $1.9 billion in 2020, at a CAGR of 14.6%. A recent research by Abbott Global shows that more than half of vascular patients globally believe that utilizing the latest diagnostic and treatment technologies can help physicians determine the best treatment plan. The study also shows that 92% of patients think that sharing their personal health information is important for future generations.

NeuroCFD® is the flagship application of Bio-CFD Inc., a U.S. based medtech startup working to harness the power of Computational Fluid Dynamics (CFD) to advance personalized medicine and bring its benefits to the bed side. “Our workflow allows medical users to learn, adapt and carry out CFD simulations easily and at scale with minimal setup routine” says Dr. Khalid Saqr, Bio-CFD’s founder and CEO.  “CFD has been serving the biomedical research community for more than three decades, now it’s the right time to bring its power to help patients in daily clinical settings” says Dr. Sherif Rashad, a neurosurgeon who uses NeuroCFD® to personalize diagnosis and management of carotid stenosis patients.

CFD simulations requires parallel computing infrastructure with extensive CPU, memory and storage resources to provide accurate and useful information. Cloud computing is the key to boost medical CFD adoption and scalability. In the last five years, many new cloud-based CFD platforms has emerged signifying the forecasted 12% CAGR to reach $3.5 billion in 2026 from $1.8 billion in 2020 of global CFD market size. “New cloud-CFD platforms share one thing: they are general purpose platforms that require users to have specialized engineering knowledge to utilize their capabilities” Says Dr. Ruggero Poletto, the CEO of CFD FEA SERVICE who provides the cloud-HPC infrastructure for NeuroCFD®. “Bio-CFD wants to give the global medical community equal access to CFD like fluid dynamics engineers” continued Dr. Saqr. Now, NeuroCFDs innovative workflow seamlessly integrates data from imaging modalities and blood picture to help patients with neurovascular disease receive personalized diagnosis and management.

Bio-CFD and CFD FEA SERVICE collaborate to empower personalized medicine

Personalized medicine promises to resolve some of the key challenges in biomedical and pharmaceutical industries. Medical simulation and digital twin technology are driving innovative prognostics, personalized clinical management and patient-specific medical devices, implants and prosthetics.

The global market size of personalized medicine surpassed $59.16 billion in 2019 and expected to reach $141.33 billion by 2027. The medical simulation sector of that market is projected to reach USD 3.7 billion by 2025 from $1.9 billion in 2020, at a CAGR of 14.6%. Bio-CFD is the world’s first computational fluid dynamics (CFD) platform for medicine and life science applications. With a first-stage mission to transform medical simulation in the $45 billion cardiovascular device market, Bio-CFD developed a cloud-computing application to personalize neurovascular disease diagnosis and management. Its operational workflow is designed to grant neurophysiologists and neurosurgeons equal access to CFD simulation capabilities like fluid dynamics engineers. “NeuroCFD is the flagship application of Bio-CFD that is designed to serve neurovascular medicine” says Dr. Khalid Saqr, the founder and CEO of the US-based medtech startup. “Our proprietary workflow allows physiologists to run hundreds of patient-specific CFD simulations on the cloud with a single few-minutes setup routine.” Dr. Saqr continued. Bio-CFD focuses on boosting CFD technology adaptability in the medical and pharmaceutical sectors. Two clinical trials are now in progress to demonstrate the clinical advantages of NeuroCFD and secure seamless FDA (SaMD) approval. The application is deployed on the cloud computing server of CFD FEA SERVICE SRL, Italy. “The innovative technology provided by Bio-CFD takes medical simulation to a new level where medical professionals are able to harness the power of CFD to directly serve patients” Says Dr. Ruggero Poletto, the general director of the Italy based cloud-computing provider who currently hosts NeuroCFD through a collaborative agreement with Bio-CFD.

Simulation of COVID-19​ Free Respirator Mask

In collaboration with Virtual Flow, we have performed one of the earliest CFD simulations for COVID-19 aerodynamics. the Flow Rate during the respiration process using Free Respirator Mask With Venturi’s valve using CFD​. The simulation was made for inlet 12 L/min flow to the venturi. A respiration simulated condition was added to the CFD simulation to determine the effect of inhaling and exhaling on the flow field. The entire case will be available on our platform.

Using 12 L/min at the Venturi inlet, we recorded at the outlet of the mask (the end of the Venturi) an average increase of twice the inlet flow rate (around 30 L/min). The representation of the recorded flow rate at Sim. 3 shows that even during exhaling the flow rate at the Mask is holding to around 30 L/min.

Medical Simulation Survey

Analysis of Community Sentiment in Focus Groups

Download the full report here

Medical simulation has recently emerged as a disruptive technology framework to accelerate innovation in medicine and life sciences. Medical simulation can accelerate discovery of new therapies, design of new medical devices and provide guidelines for clinical trials and regulatory approval.

Since medical simulation involves different stakeholders, its community is diverse presenting engineers, healthcare professionals, regulatory body professionals among other expertise. This is the first qualitative survey on medical simulation to evaluate the community sentiment.

Participants were recruited anonymously from focus groups on social media platforms. A simple sentiment model was established to analyze the results. Total participants were 131 from 5 focus groups.

The overall results showed positive sentiment at 60.31% of the participants, neutral sentiment at 36.64% and negative sentiment at 3.05%. Positive sentiment was reported by 75% of regulatory body professionals and 61.5% by healthcare professionals. All the detailed results and methodology are reported in this document and is shared with the community under CC BY SA 4.0 open-access license.

NeuroCFD is the future of endovascular surgery simulation

Not all arteries are created equal!

The carotid artery disease market is expected to hit USD 11.6 Billion by 2023. This includes Diagnosis (Computed Tomography Angiography, Carotid Ultrasound, & Magnetic Resonance Angiography), Treatment (Medications & Surgical Procedures), & End User (Hospitals & Clinics). The major restraints of the market are the high cost of diagnostics and surgeries as well as stringent government regulations. NeuroCFD resolves these restraints by offering a new decision support tool to critically evaluate the outcome of common carotid artery endovascular surgery procedures. NeuroCFD is the flagship application of Bio-CFD, the world’s first CFD platform for biomedical and pharmaceutical applications.

NeuroCFD brings unlimited simulation power to this staggeringly growing market. The software is designed to offer intelligent user experience to neurosurgeons and neuroradilogists. Its cloud-based solver facilitates bulk simulation of hundreds of cases with one easy workflow. Patient-specific simulations to evaluate the outcome of carotid angioplasty and surgery are available to everyone without any prerequisite knowledge of computational fluid dynamics. The meshing and solution setup of NeuroCFD offer carefully designed and validated templates to automatically simulate carotid angioplasty and stenting (CAS), extracranial aneurysm stenting and flow diversion.

Follow us on Twitter and Linkedin to stay tuned and take part in the launch of NeuroCFD.

NeuroCFD is one step away!

We are excited to announce that NeuroCFD, our flagship solver, is ready!

NeuroCFD is designed and optimized to simulate blood flow in the circle of Willis. Its intuitive and streamlined workflow provide unparalleled user experience. Patient-specific simulations have never been easier! With automated mesh and boundary condition features, you can run hundreds of patient-specific simulations of cerebral hemodynamics on the clouds with a single, one-time, workflow!

Follow us on twitter to stay tuned!

Bio-CFD Reproducibility Index

Bio-CFD has released the first reproducibility index for CFD simulations in biomedical applications. The index classifies CFD simulations according to their reproducibility criteria to allow the scientific community to save time and effort in building verified and validated CFD simulations. The concept is inspired by a recent study conducted on COVID-19 airborne transmission using CFD. The application issues a unique reproducibility index (URI) to eligible simulations free of charge and it is accessible via this link. The simulation registrar (user) simply fills in some information to a Google form which generates a basic/initial index automatically. Then, our team will evaluate the application and issue the final URI within 48 hours.

Partnership with Virtual Flow

Bio-CFD has partnered with Virtual Flow to implement its cloud-based CFD platform. Virtual flow has a team of CFD engineers who have proven experience in developing open-source CFD solvers for numerous and diverse applications. The partnership aims at ensuring sustainable and efficient cloud implementation of Bio-CFD solvers and tools.

Large Eddy Simulation unveils ischemic attack in Moyamoya patients

Researchers from Tohoku University have unveiled the causes of transient ischemic attacks (TIAs) in early-stage Moyamoya patients using Large Eddy Simulation. The study, published in Nature’s Scientific Reports showed that complex hemodynamic interactions, driven by momentum-viscous interactions with blood’s non-Newtonian viscosity, cause multiple mechanisms that lead to cerebral blood insufficiency. Loss of phase-shift, Rankine vortex and local elevated viscosity structures impedes blood flow in diseased arteries.